In return, Mayo receives equity stakes in the participating companies
staff at the Mass Spectrometry Resource Laboratory in the Center for Advanced Research Technologies (CART) and the Histology, Biochemistry, and Molecular Imaging (HBMI) Core at the Center for Musculoskeletal Research (CMSR) at URMC, the Proteomics/Metabolomics Core at Moffitt Cancer Center, which is funded in part by Moffitts Cancer Center Support Grant (P30CA076292), and University of Chicago Metabolomics Platform (RRID: SCR_022932)
So if retatrutides phase 3 trials finish in 2025 or early 2026, approval and market availability by late 2026 or 2027 is a plausible target assuming all goes well
Phase 3 TRIUMPH-1 NCT05929066, TRIUMPH-2 NCT05929079, TRIUMPH-3 NCT05882045, TRIUMPH-4 NCT05931367, TRIUMPH-Outcomes NCT06383390
Detoxification: Helps in the removal of toxins from the body